updat thought
expect re-emerg competit player hem
gene therapi detail launch note maintain
expect favor clinic develop hem preclin
profil demonstr dose respons suggest drug may offer
high potenc across fairli broad therapeut window rel low dose
level possibl lead differenti support spark product
translat spark manag commentari base
analysi histor comment believ recent manag
commentari earn call feb reinforc optim ahead
next updat best-cas scenario would
exit clear clinic dose respons go-forward dose
identifi set start management state target
consist fviii activ level think target product profil hem
gene therapi would produc fviii activ level ideal within
normal rang patient analysi suggest could
enough evid dose support next updat
possibl remain evid end
reiter outperform rais tp
rais program po higher bake
optimist stanc peak market share peak sale
program increas continu
like spark unencumb clinical-stag pure play hem
gene therapi assumpt around biomarin valrox unchang
continu see product hold favor posit lt data
patient year lead competitor risk thesi
includ clinic trial delays/failur posit updat competitor
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
spark biotechnolog compani focus
develop commerci gene therapi treatment
price rate outperform target price analyst tin auster
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
cash-flow financ activ
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
 close
establish consist predict
fviii express level amen safeti profil face
signific reimburs hurdl luxturna
fail develop/identifi competit product profil spk-
lose pipeline/technolog valu face
reimburs challeng luxturna
statu non-u analyst us disclosur credit suiss seek busi compani cover research report result
investor awar firm may conflict interest could affect object report investor consid report singl
factor make invest decis
believ potenti re-emerg competit player hem gene therapi
despit inconclus updat experi gene therapi program hemophilia
valrox suggest data present within expect rang inter/intra-pati variabl believ
larger matur dataset requir start defin product profil think spark expertis track record
warrant higher confid program
updat may provid robust dataset meaning progress establish pivot dose
stagger process complet enrol new patient recent manag commentari emphas
increas effort recruit subject trial think trial pace pick
assum spark patient week per week hem reflect larger hem popul vs activ
site data patient week follow wfh may patient
cohort isth juli
manag messag expect past translat recent commentari optimist
believ recent commentari suggest spark confid fviii level stabil week spark
want comfort north across patient go-forward dose spark think dose
hem market accommod gene therapi player
expect slow-ish penetr gene therapi hemophilia pre-exist neutral antibodi versu aav
vector larg size market opportun support hem market accommod gene therapi player
level differenti facilit spark achiev commerci outlook product possibl
via lower dose level could lead lower and/or narrower/low variabl rang factor express
posit mid-year updat start restor investor confid program
see next updat first step determin lt valu asset intermedi basi
see upsid scenario driven higher po market assumpt support clear dose
respons emerg evid potenti go-forward dose look stabl consist fviii level
could credibl occur clariti could send share lower end recent
rang lack clariti end may lead investor write-off program
frequent receiv follow two question investor
spark present enough data next updat expect demonstr
dose respons possibl go-forward dose
spark like least year behind biomarin valrox data expect end
what market opportun second mover like
degre need differenti other
luxturna remain talk point hem like drive move
hem updat inconclus due small
sampl size spark updat enough
data establish dose respons may suggest futur
pivot dose confirm pivot trial
start end
spark success develop hem program
get luxturna approv fda earn
higher po assumpt investor
compani extens cmc/regulatori gene tx expertis
hem gene tx us opportun
support multipl gene therapi player gene therapi
like take sever year gain wide adopt allow
opportun mover unencumb
pure-play spark highli attract acquisit target
over-scrutini luxturna launch miss big pictur
short-term uptak curv irrelev vast
major address patient treat eventu
differ best/worst case scenario
meaningless driver rel
updat messi dose
respons individu patient data place
competit get patient
normal fviii rang bar normal
given present far updat
wont offer clariti dose-respons potenti
go forward dose wont enough patient follow
suffici time spark may even need dose
could delay program possibl
even push spark back posit among hem
biomarin valrox dose offer
incred hard spark differenti
need one gene therapi
luxturna address popul hard specif
pin launch may disappoint
spark present data four patient follow
week updat gener
dose respons intra/interpati variabl
previou without-a-hitch success hem
lack clear dose respons follow previou updat
share promis data first subject
data didnt show clear dose respons two-fold dose
increas cohort
data high intra-pati variabl
factor level stabil spike factor level
unclear updat fviii level stabil
week post infus seen hem
known reason spike factor level
week particip
subject receiv corticosteroid cours unclear
factor level stabil
believ investor fail appreci
spark provid high level detail limit sampl size
low end expect dose rang
two-fold dose increas marker
vari
dose level pose challeng
interpati
extrapol small sampl
compani data present decemb cutoff
despit initi reaction experi gene therapi program hemophilia
valrox suggest data within expect rang larger matur dataset
requir start defin product profil
confid part
preclin profil demonstr dose respons high potenc
adequ
product profil rel low dose clinic
contain codon-optim human factor viii gene
proof-of-concept well establish non-human primat
dose respons across dose cohort therapeut
level express
fviii activ level dose respons non-human primat
preclin data suggest capsid
superior transduct effici nhp compar
capsid util
success hem
candid higher fviii level
capsid also compar favor term pre-
exist neutral antibodi aav
neg two assay total antibodi transduct inhibit
preliminari result phase aav gene therapi
trial hemophilia present
preclin data suggest high potenc specif
preclin clinic data suggest higher potenc
valrox lower dose express level
wider rang dose escal necessari
achiev target product profil
lower dose may desir reduc advers event
alt elev
confid part
spark develop current best-in-
class profil hemophilia gene therapi
seriou advers event relat gene therapi
averag express level normal first
subject enrol week
four particip month maintain stabl factor
spark enrol five addit subject four quarter
dose product
enhanc
manufactur process transfer partner pfizer
expect summer ahead start
takeaway program
first dose human achiev desir factor express
rang dose escal conduct
spark/pfiz decid expand enrol cohort
instead pursu dose escal base publish data
subject beyond week
cohort highest express level
lowest express level
week mark rang factor level roughli
express level becam rel
stabl week
subject exhibit delta
measur interv even week dose
roughli return previou level
enrol speed pivot decis
first subject spark enrol averag one
compani data present novemb latest updat cutoff
sprechen sie spark speak spark
manag messag expect past translat recent
commentari optimist
high level though chang
clear sort head room import think achiev level high
introduc potenti safeti risk spoke even back august call thatwewantedtoensurethatwetook
thetimeinphasei/iitodotheworknecessarytotestvariousdosesandmakesureweunderstood fulli
propertiesandthecharacteristicsofthevectorinallthosevariousdos said earlier call
kathi mention prepar remark execut dose-escal studi way plan come
studi jeffrey marrazzo
read dose might get us well like need explor higher level
dose vector genom per kilogram safe far import develop
also acceler enrol eye toward generatingarobustdatasettoselectourdosefrom
vector genom per kilogram eye toward
identifi best dose safeti efficaci profil jeffrey marrazzo
read spark seem optimist dose may viabl go-forward dose
tinctur time ithinkatthenextdisclosureofdata youwillunderstandthatthekineticsofthisfactor
viiivectorissimilartowhatw veseenforfactorix period increas factor activ patient
give take
sort number durabl -- durat follow-up look prior formul plan phase
would say see differ hemophilia hemophilia katherin high
preclin datawould support higher dose point wehavenoplanstoamendtheprotocoltogo
read spark confid fviii level stabil week spark want comfort
north across patient go-forward dose cohort spark think dose level may
robust dataset expect updat
spark dose patient dose level
stagger process complet enrol new patient think trial pace could pick
assumpt patient dose week per week hem reflect larger hem popul vs activ site
framework think spark could present data patient week follow
wfh may patient cohort isth juli
possibl patient month data dose isth suggest next updat could meaning
establish dose respons go-forward plan
exampl enrol timelin avail data updat
data present
potenti new data present
week data
per subject
assum one patient dose everi week post updat
updat potenti scenario expect
subject
 stabl consist
fviii level
stabil fviii level
week
durabl effect earli pt
achiev high dose
express time
need dose
escal
establish go-
need sampl
week data higher dose
data possibl
subject go-forward
dose
week follow-up
potenti one two
earli sign go-forward
dose need
enrol addit subject
level anoth
unclear updat
possibl need consid
reformul
discontinu
base lower dose
possibl later
seem less like
competitor hem
owe
higher po market-
establish
sinc pure-play gene
therapi player de-
clariti could
send share lower end
lack clariti may
lead investor write-off
program
lead elev risk
 shire
pfe/sgmo move
market opportun hemophilia support player
patient popul
substanti
upsid
hemophilia patient us
hemophilia patient us high cost standard care
see tremend commerci potenti gene therapi indic
target popul
time address popul expand
like mod/sever patient histori inhibitor aav
neutral antibodi us see opportun number grow
row address popul multi-fold us
us lump sum net price project year ehl therapi price repres
opportun us row assum annual reimburs compar level
ehl therapi
clinician prefer aav neutral antibodi open opportun two product
compet larg market unlik multipl player co-exist fviii market today
expect conserv uptak initi earli commerci outcom posit expect
gene therapi share rapidli gain traction year launch
substanti revenu risk expect increas interest larger biopharma player
fviii replac therapi class
shire hem gene therapi
program clinic data avail
bayer expect file ind hem
program
partnership sangamo
hem program earli clinic data
spark could pure-play gene therapi player readi unpartn
program hemophilia like draw signific interest potenti acquir
explor role second-mov hem gene tx
still area potenti differenti
believ like slow penetr gene therapi target popul potenti pre-exist
neutral antibodi versu aav vector size market opportun support hem market
accommod two gene therapi player
compani substanti commerci interest hem space also like
drive competit think would consist multipl player factor replac market
spark player may trail biomarin valrox year market think level
differenti would essenti maxim uptak product possibl area
differenti view driven like lower therapeutically-relev dose need treat
dosag safeti
narrow rang
therapeut level
factor non/hyp
lower dose could potenti lead amen safeti profil case alt
elev seen major patient valrox phase studi potenti relat
high aav dose least higher cohort lower dose could result
amen safeti profil reduc need corticosteroid treatment
rel reduc variabl respons valrox data show rel high variabl
dose mix/max one low respons dose observ phase
first updat show variabl earli believ dataset
incompat narrow rang respons patient reach steady-st level like
week product offer predict narrow respons rang
still deliv factor level express prefer normal may seen
favor patient doctor think possibl lower aav dose may yield less
variabl efficaci respons time though pure hypothet stage
revenu build valuat sensit
greater confid program increas tp
revenu build assum commerci global basi though think
compani could becom attract consolid target and/or may consid ou partner revenu build
base case make follow assumpt
us lump-sum net price million reflect five year prophylact factor replac
ou annualnet price reflect performance-bas model award small premium
averag cost prophylact factor replac therapi plu associ cost
gene therapi penetr overal expect gene therapi captur us
patient never inhibitor neutral aav antibodi within ten year market
po market share increas po
long-term market-shar take tp
base case
increas program po add valuat
increas long-term market share add valuat
year market penetr
total patient treat gene therapi
patient treat gene therapi year
model assumpt may prove conserv esp row assum penetr rate
rel us despit high need new therapi gener poorer outcom us
preclin profil lead hem gene therapi
develop suspens
on-going phase dose
vg/kg
baculoviru system pre-
pivot dose human
vg/kg
start dose vg/kg rang
believ spark dose respons curv
product profil balanc potenc
level ampl room dose
escal without risk overshoot
bmrn dose respons curv non-human
/consist clinic data human
saw much steeper dose-
potenc construct data human
experi highlight possibl swift trial progress
variabl longer period reach steady-st
express rel hemophilia
vg/kg fviii express rang
week
vg/kg fviii express rang
week one patient saw fviii spike week
return wk
biomarin phase studi found take week
fviii level stabil
compani current conduct two registr
trial one vg/kg one vg/kg
fviii activ vg/kg dose
takeaway program
enrol speed quick enrol complet
dose escal phase complet
patient vg/kg took wk
enrol addit patient dose
vg/kg enrol two wave patient
november/decemb februari march patient dose
february/march treat within wk period
compani list site particip studi site
uk
pivot decis made wk data
initi decis august move pivot trial
treatment vg/kg patient
patient far dose factor level rang
proceed phase compani announc dose
decis take dose pivot trial wk
data patient dose level patient
around wk data
concurr
limit read-through biomarin valrox
think biomarin valrox make-or-break merit
despit possibl experi volatil depend qualiti spark next hem
gene therapi updat see read-through bmrn hemophilia gene therapi program valrox limit
valrox yr lead project yr market entranc success/failur program bmrn control
assign long-term market share account spark command lt market share
account increment posit spark updat setback spark program could support upsid
first-mov advantag flexibl clinic develop strategi lead pursu vg/kg
dose phase support base assumpt bmrn lt competit posit space
patient treat gene therapi per year
cumul patient treat gene therapi
suspens
pre-clin
rang week
phase studi plan target
enrol subject pt
studi enrol dec
enrol studi start
biomarin also begin phase studi
pt posit enrol
expect start
addit phase data summer
continu enrol next data
readout
week week
week week
addit subject dose
start dose vg/kg rang base
 subject potenti dose cohort
subject cohort recent amend
subject put
drop fviii
indic desir amend protocol
dose higher vg/kg
subject alreadi dose anoth
expect dose soon first patient
dose august trial activ site
compani mention price
